PV Watch Daily Blog
Fresh reporting, analysis, and expert insight on drug safety, regulatory developments, safety signals, inspections, AI in pharmacovigilance, and career trends.
Week in PV: FDA B6 Warning, GLP-1 Label Change and PRAC Updates
This week’s major U.S. developments include FDA’s requirement for a vitamin B6 deficiency and seizure warning on carbidopa/levodopa products and the agency’s...
CTIS Sponsor Training in June 2026 Signals the Growing Importance of Trial-System Skills
EMA has scheduled a CTIS sponsor end-user training programme for 8–11 June 2026. The event listing places the training firmly within the live operational...
Why MHRA’s Weekly Field Safety Notices Still Matter for Safety Monitoring
MHRA published Field Safety Notices: 9–13 March 2026 on 17 March 2026, listing device-related notices within its alerts, recalls, and safety-information...
Ramipril Recall After Packaging Error Raises Medication Mix-Up Risk
MHRA said Crescent Pharma Limited is recalling one batch of Ramipril 5 mg Capsules as a precautionary measure after a potential manufacturing error may have...
Why MHRA’s Weekly Field Safety Notices Still Matter for Safety Monitoring
MHRA published Field Safety Notices: 9–13 March 2026 on 17 March 2026, listing device-related notices within its alerts, recalls, and safety-information...
Ramipril Recall After Packaging Error Raises Medication Mix-Up Risk
MHRA said Crescent Pharma Limited is recalling one batch of Ramipril 5 mg Capsules as a precautionary measure after a potential manufacturing error may have...
FDA Approves Wegovy HD in 54 Days Under Priority Voucher Pilot
FDA announced on 19 March 2026 that it approved Wegovy HD (semaglutide 7.2 mg) for weight loss and long-term weight maintenance in certain adults. The agency...
What EMA’s 2026 Biologics Safety Page Signals About Ongoing Regulator Transparency
FDA’s 2026 Safety and Availability Communications page for biologics says it was developed to provide the public with important information about the safety...
Global Watch Weekly: MHRA, EMA Shortages and Veterinary Developments
MHRA approved deuruxolitinib for severe alopecia areata in adults and explicitly said it would continue to keep the medicine’s safety and effectiveness under...
Week in PV: FDA B6 Warning, GLP-1 Label Change and PRAC Updates
This week’s major U.S. developments include FDA’s requirement for a vitamin B6 deficiency and seizure warning on carbidopa/levodopa products and the agency’s...